Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ORGANIZATION
ORGANIZATION
- JPMA Reprimands Celgene over Side Effect Reporting Violation
March 24, 2017
- Use “Specified Clinical Research” Data for Drug Approval: Regulatory Science Society
March 23, 2017
- Study Group Presents Proposal for Future Vision for Kampo Medicines
March 21, 2017
- Industry Wants Real-World Data to Serve as Grounds for Drug Pricing: JPMA Head
March 7, 2017
- EFPIA Japan to Compile Policy Proposal on Pricing Reform by Early April: New Chair
March 1, 2017
- 3 Groups to Draw Up Guidelines on Inter-Pharmacy Drug Transactions by March-End
February 27, 2017
- US Exclusion from Foreign Price Adjustment Should Be Carefully Considered: PhRMA Japan Chief
February 2, 2017
- JMA Calls for Tighter Penalties on Parties Involved in Counterfeits
January 26, 2017
- JPMA Sets Up New Unit as Liaison for APAC
January 20, 2017
- NPhA Instructing Member Pharmacies on Careful Drug Purchases after Fake Harvoni Issue: Chief
January 20, 2017
- JGA Head Frets Majority of Products Subject to Gap-Year Revisions Will Be Generics
January 20, 2017
- We Must Redouble Efforts for Proper Drug Distribution, Pharmacist Group Says on Fake Harvoni Issue
January 19, 2017
- OTC Industry Group Keen on Expanding Self-Medication Tax Break: Chief
January 18, 2017
- JPMA Eager for Its Active Involvement in Drug Pricing Debates: Chief
January 18, 2017
- JMA’s Nakagawa Pushes Price Cuts Even on Non-100 Billion Yen Products, Eyes Other Hep C Drugs
January 18, 2017
- JGA Corrects Generic Share Data for Past 3 Years; July-Sept. Share at 65.1%
January 16, 2017
- With Annual Revisions, Drug Wholesalers Will Be Negotiating Delivery Prices All Year: JPWA Chief
January 12, 2017
- Tokyo Pharma Chief Naito Prods Govt to Secure Predictability of Pricing System
January 10, 2017
- Building Personal Relationships Will Be Crucial: FPMAJ Director General
January 6, 2017
- Annual Price Revisions Must Not Adversely Affect Distribution Environment: JPWA
December 26, 2016
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…